184 related articles for article (PubMed ID: 12214578)
1. Clinical-pharmacokinetic aspects of prolonged effect duration as illustrated by beta2-agonists.
Rosenburg J
Eur J Clin Pharmacol; 2002 Jul; 58(4):S1-21. PubMed ID: 12214578
[TBL] [Abstract][Full Text] [Related]
2. The use of inhaled formoterol in the treatment of asthma.
Berger WE
Ann Allergy Asthma Immunol; 2006 Jul; 97(1):24-33. PubMed ID: 16892777
[TBL] [Abstract][Full Text] [Related]
3. Formoterol. An update of its pharmacological properties and therapeutic efficacy in the management of asthma.
Bartow RA; Brogden RN
Drugs; 1998 Feb; 55(2):303-22. PubMed ID: 9506248
[TBL] [Abstract][Full Text] [Related]
4. Effects of treatment with formoterol on bronchoprotection against methacholine.
Lipworth B; Tan S; Devlin M; Aiken T; Baker R; Hendrick D
Am J Med; 1998 May; 104(5):431-8. PubMed ID: 9626025
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and tolerability of formoterol in healthy volunteers after a single high dose of Foradil dry powder inhalation via Aerolizer.
Lecaillon JB; Kaiser G; Palmisano M; Morgan J; Della Cioppa G
Eur J Clin Pharmacol; 1999 Apr; 55(2):131-8. PubMed ID: 10335908
[TBL] [Abstract][Full Text] [Related]
6. Relative systemic dose potency and tolerability of inhaled formoterol and salbutamol in healthy subjects and asthmatics.
Rosenborg J; Bengtsson T; Larsson P; Blomgren A; Persson G; Lötvall J
Eur J Clin Pharmacol; 2000 Aug; 56(5):363-70. PubMed ID: 11009043
[TBL] [Abstract][Full Text] [Related]
7. Cumulative high doses of inhaled formoterol have less systemic effects in asthmatic children 6-11 years-old than cumulative high doses of inhaled terbutaline.
Kaae R; Agertoft L; Pedersen S; Nordvall SL; Pedroletti C; Bengtsson T; Johannes-Hellberg I; Rosenborg J
Br J Clin Pharmacol; 2004 Oct; 58(4):411-8. PubMed ID: 15373934
[TBL] [Abstract][Full Text] [Related]
8. Beta2-adrenoceptor polymorphism and bronchoprotective sensitivity with regular short- and long-acting beta2-agonist therapy.
Lipworth BJ; Hall IP; Aziz I; Tan KS; Wheatley A
Clin Sci (Lond); 1999 Mar; 96(3):253-9. PubMed ID: 10029561
[TBL] [Abstract][Full Text] [Related]
9. Formoterol in clinical practice--safety issues.
Rabe KF
Respir Med; 2001 Aug; 95 Suppl B():S21-5. PubMed ID: 11534893
[TBL] [Abstract][Full Text] [Related]
10. Sustained bronchoprotection, bronchodilatation, and symptom control during regular formoterol use in asthma of moderate or greater severity. The Canadian FO/OD1 Study Group.
FitzGerald JM; Chapman KR; Della Cioppa G; Stubbing D; Fairbarn MS; Till MD; Brambilla R
J Allergy Clin Immunol; 1999 Mar; 103(3 Pt 1):427-35. PubMed ID: 10069876
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the efficacy, tolerability and patient acceptability of once-daily bambuterol tablets against twice-daily controlled release salbutamol in nocturnal asthma. ACROBATICS Research Group.
Gunn SD; Ayres JG; McConchie SM
Eur J Clin Pharmacol; 1995; 48(1):23-8. PubMed ID: 7621843
[TBL] [Abstract][Full Text] [Related]
12. Budesonide/formoterol for maintenance and relief in uncontrolled asthma vs. high-dose salmeterol/fluticasone.
Bousquet J; Boulet LP; Peters MJ; Magnussen H; Quiralte J; Martinez-Aguilar NE; Carlsheimer A
Respir Med; 2007 Dec; 101(12):2437-46. PubMed ID: 17905575
[TBL] [Abstract][Full Text] [Related]
13. Effects of the long acting beta agonist formoterol on asthma control in asthmatic patients using inhaled corticosteroids. The Netherlands and Canadian Formoterol Study Investigators.
van der Molen T; Postma DS; Turner MO; Jong BM; Malo JL; Chapman K; Grossman R; de Graaff CS; Riemersma RA; Sears MR
Thorax; 1997 Jun; 52(6):535-9. PubMed ID: 9227720
[TBL] [Abstract][Full Text] [Related]
14. One month treatment with the once daily oral beta 2-agonist bambuterol in asthmatic patients.
Persson G; Baas A; Knight A; Larsen B; Olsson H
Eur Respir J; 1995 Jan; 8(1):34-9. PubMed ID: 7744191
[TBL] [Abstract][Full Text] [Related]
15. Inhaled corticosteroids or long-acting beta-agonists alone or in fixed-dose combinations in asthma treatment: a systematic review of fluticasone/budesonide and formoterol/salmeterol.
Frois C; Wu EQ; Ray S; Colice GL
Clin Ther; 2009 Dec; 31(12):2779-803. PubMed ID: 20110019
[TBL] [Abstract][Full Text] [Related]
16. Beta2-adrenoceptor regulation and bronchodilator sensitivity after regular treatment with formoterol in subjects with stable asthma.
Aziz I; Hall IP; McFarlane LC; Lipworth BJ
J Allergy Clin Immunol; 1998 Mar; 101(3):337-41. PubMed ID: 9525449
[TBL] [Abstract][Full Text] [Related]
17. Comparative study using oral solutions of bambuterol once daily or terbutaline three times daily in 2-5-year-old children with asthma. Bambuterol Multicentre Study Group.
Kuusela AL; Marenk M; Sandahl G; Sanderud J; Nikolajev K; Persson B
Pediatr Pulmonol; 2000 Mar; 29(3):194-201. PubMed ID: 10686040
[TBL] [Abstract][Full Text] [Related]
18. Acute relief of exercise-induced bronchoconstriction by inhaled formoterol in children with persistent asthma.
Hermansen MN; Nielsen KG; Buchvald F; Jespersen JJ; Bengtsson T; Bisgaard H
Chest; 2006 May; 129(5):1203-9. PubMed ID: 16685010
[TBL] [Abstract][Full Text] [Related]
19. Comparison of formoterol and terbutaline for as-needed treatment of asthma: a randomised trial.
Tattersfield AE; Löfdahl CG; Postma DS; Eivindson A; Schreurs AG; Rasidakis A; Ekström T
Lancet; 2001 Jan; 357(9252):257-61. PubMed ID: 11214127
[TBL] [Abstract][Full Text] [Related]
20. Comparison between a new once-daily, bronchodilating drug, bambuterol, and terbutaline sustained-release, twice daily.
Persson G; Gnosspelius Y; Anehus S
Eur Respir J; 1988 Mar; 1(3):223-6. PubMed ID: 3384075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
